Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Health Service Bureau Increases Budgets for Measures against Hepatitis, Infectious Diseases: FY2016 Draft Budget
January 5, 2016
- Gist of FY2016 Drug Pricing Reform
December 25, 2015
- Chuikyo OKs Outline of FY2016 Drug Pricing Reform
December 25, 2015
- 130 Million Yen Earmarked to Boost PMDA Staffers for Accelerating Review: FY2016 Budget
December 25, 2015
- MHLW Looked at Innovativeness, Seriousness of Target Disease to Select Sakigake Products
December 25, 2015
- MHLW Launches Confab to Shore Up Healthcare Startup Sector
December 25, 2015
- Drug Price Cuts to Save 174.9 Billion Yen in State Coffers: MOF
December 25, 2015
- FY2016 Draft Budget Includes 82.5 Bil. Yen to Promote Creation of Innovative New Drugs and Medical Devices
December 25, 2015
- AMED-Led Screening Consortium Gets Underway with 22 Japanese Makers
December 24, 2015
- Plavix, 15 Other Brands to Lose Premiums on Generic, Biosimilar Entries; Re-Pricing Could Deal Another Blow
December 24, 2015
- MHLW OKs Add’l Indications for Remicade, Other Drugs
December 22, 2015
- Drug Prices to Be Pared 7.8% If Re-Pricing, Z2, Generic Price Cuts Included
December 22, 2015
- 3.6 Billion Yen in FY2015 Extra Budget to Go to IFN-Free Hep C Therapies
December 21, 2015
- Japan, India Sign Memorandum for Regulatory Affairs
December 21, 2015
- MHLW Grants Orphan Drug Designation for Sakigake Product Sirolimus, Others
December 21, 2015
- Govt to Shed 28 Bil. Yen via Huge Seller Drugs, 20 Bil. Yen via Existing Re-Pricing Rule; Physicians to Win “Plus” Revision
December 21, 2015
- Shipments of Kaketsuken’s Hep B Vaccine Likely to Resume Early Next Year
December 18, 2015
- MHLW to Carefully Discuss Cost Effectiveness of Prevenar 13 for Its Elderly Use under National Program
December 18, 2015
- ICH Reaches Agreement to Treat Subjects with Similar Ethnic Factors as Single Populations Regardless of Nationality
December 18, 2015
- PMDA Beating Targets for Overall Review Time in FY2015
December 18, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…